Aurobindo Pharma gets USFDA nod for Glycerol Phenylbutyrate Oral Liquid for urea cycle disorders, to launch from Unit III, US market about 50.2 million dollars, shares edge higher.
Aurobindo Pharma gets USFDA nod for Glycerol Phenylbutyrate Oral Liquid for urea cycle disorders, to launch from Unit III, US market about 50.2 million dollars, shares edge higher.